MA50506A - Composé triazine et sel pharmaceutiquement acceptable de celui-ci - Google Patents

Composé triazine et sel pharmaceutiquement acceptable de celui-ci

Info

Publication number
MA50506A
MA50506A MA050506A MA50506A MA50506A MA 50506 A MA50506 A MA 50506A MA 050506 A MA050506 A MA 050506A MA 50506 A MA50506 A MA 50506A MA 50506 A MA50506 A MA 50506A
Authority
MA
Morocco
Prior art keywords
pharmaceutically acceptable
acceptable salt
triazine compound
triazine
compound
Prior art date
Application number
MA050506A
Other languages
English (en)
Inventor
J John Talley
Liangliang Xu
Xuan Yang
Chenggang Zhu
Original Assignee
Shenzhen Forward Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Forward Pharmaceuticals Co Ltd filed Critical Shenzhen Forward Pharmaceuticals Co Ltd
Publication of MA50506A publication Critical patent/MA50506A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050506A 2017-05-15 2018-05-15 Composé triazine et sel pharmaceutiquement acceptable de celui-ci MA50506A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710339199.4A CN108864079B (zh) 2017-05-15 2017-05-15 一种三嗪化合物及其药学上可接受的盐

Publications (1)

Publication Number Publication Date
MA50506A true MA50506A (fr) 2020-09-09

Family

ID=64274085

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050506A MA50506A (fr) 2017-05-15 2018-05-15 Composé triazine et sel pharmaceutiquement acceptable de celui-ci

Country Status (4)

Country Link
EP (1) EP3705478B1 (fr)
CN (2) CN108864079B (fr)
MA (1) MA50506A (fr)
WO (1) WO2018210246A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111747931A (zh) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
CN111925366B (zh) * 2019-05-13 2024-04-09 广东阿格蕾雅光电材料有限公司 一种咪唑并氮杂环化合物及其应用
TW202128670A (zh) * 2019-11-26 2021-08-01 大陸商上海翰森生物醫藥科技有限公司 含氮多環類衍生物抑制劑、其製備方法和應用
KR20230026383A (ko) * 2020-06-23 2023-02-24 선전 포워드 파머수티컬즈 코 엘티디 화합물의 염 및 염을 포함하는 약학적 조성물
CN115836064B (zh) * 2020-08-13 2024-08-27 上海和誉生物医药科技有限公司 具有egfr抑制活性的三嗪衍生物及其制备方法和应用
EP4257584A4 (fr) * 2020-12-02 2024-07-31 Abbisko Therapeutics Co., Ltd. Dérivé de 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine, son procédé de préparation et son utilisation
CN116670126A (zh) * 2021-05-13 2023-08-29 上海和誉生物医药科技有限公司 具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用
EP4382511A4 (fr) * 2021-08-06 2025-07-30 Abbisko Therapeutics Co Ltd Dérivé de pyrimidine ou de pyridine, son procédé de préparation et son application en pharmacie

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0880508T3 (da) 1996-02-13 2003-06-30 Astrazeneca Ab Quinazolinderivater som VEGF-inhibitorer
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20080015482A (ko) 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
EP1289952A1 (fr) 2000-05-31 2003-03-12 AstraZeneca AB Derives d'indole possedant une activite endommageant les vaisseaux sanguins
AU2001266232B2 (en) 2000-07-07 2005-09-15 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2015188747A1 (fr) * 2014-06-12 2015-12-17 南京圣和药业股份有限公司 Composé de triazine substitué par phényle servant d'inhibiteur de l'egfr et ses applications
GEP20197011B (en) * 2014-06-19 2019-08-12 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
CN105461695B (zh) * 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
WO2017035753A1 (fr) * 2015-08-31 2017-03-09 无锡双良生物科技有限公司 2-arylamino pyridine, dérivé de pyridine ou de triazine, leur procédé de préparation et leur utilisation
CN106928200A (zh) * 2015-12-30 2017-07-07 湖南福沃药业有限公司 用于治疗癌症的三嗪衍生物
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
CA3023176A1 (fr) * 2016-05-26 2017-11-30 Zeno Royalties & Milestones, LLC Composes inhibiteurs de l'egfr

Also Published As

Publication number Publication date
CN110891950A (zh) 2020-03-17
CN108864079A (zh) 2018-11-23
EP3705478A1 (fr) 2020-09-09
EP3705478A4 (fr) 2020-10-28
WO2018210246A1 (fr) 2018-11-22
CN108864079B (zh) 2021-04-09
EP3705478B1 (fr) 2023-10-04
CN110891950B (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
ZA202001340B (en) Heterocyclic compound and use thereof
MA50506A (fr) Composé triazine et sel pharmaceutiquement acceptable de celui-ci
EP3805198A4 (fr) Composé, sel de celui-ci et particules lipidiques
EP3896060A4 (fr) Composé hétérocyclique
ZA201807249B (en) Heterocyclic compound
EP3895707A4 (fr) Composé hétérocyclique
EP3438109A4 (fr) Composé hétérocyclique
MA45940A (fr) Composé hétérocyclique
EP3689879A4 (fr) Composé hétérocyclique
EP3366684A4 (fr) Composé hétérocyclique
EP3327019A4 (fr) Composé hétérocyclique
EP3560925A4 (fr) Nouveau composé et sel pharmaceutiquement acceptable de celui-ci
EP3444239A4 (fr) Composé hétérocyclique
EP3366679A4 (fr) Composé hétérocyclique
EP3888652A4 (fr) Composé hétérocyclique
EP3424905A4 (fr) Composé hétérocyclique
EP3578549A4 (fr) Composé hétérocyclique
MA44781A (fr) Composé hétérocyclique condensé
MA52297A (fr) Composé hétérocyclique
EP3660003A4 (fr) Composé hétérocyclique
PT3643718T (pt) Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1
EP3693368A4 (fr) Composé hétérocyclique
EP3444245A4 (fr) Composé hétérocyclique
EP3409662A4 (fr) Nouveau composé et sel pharmaceutiquement acceptable de celui-ci
EP3643718A4 (fr) Composé hétérocyclique